NCT05600920: A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 60 planned
- Started
- 6 Nov 2024
- Primary completion
- 1 Nov 2026
- Arms
- Single Cohort
- Results
- None posted
- 1 Nov 2022: Trial registered
- 6 Nov 2024: Trial started